SignalCorporate
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
Q3 loss and missed revenue estimates signal earnings underperformance.
Context
What happened: NRx Pharmaceuticals (NRXP) reported a Q3 loss of $0.05 per share versus the Zacks Consensus Estimate of a $0.29 loss, and revenue of $1.16 million missed the consensus estimate by 14.15%.
Key numbers: Loss per share $0.05 vs. $0.29 expected and $0.18 a year ago. Earnings surprise +82.76%.
Why it matters: The estimate revisions trend ahead of the release was unfavorable, translating into a Zacks Rank #5 (Strong Sell), and the shares are expected to underperform the market in the near future. The company has not beaten consensus revenue estimates over the last four quarters.
Market: -0.6% today ($172.92), +25.9% YTD, 0.8x vol — as of 00:45 UTC
Coverage: 4 outlets in 24h
What changed
NRx Pharmaceuticals (NRXP) reported a Q3 loss of $0.05 per share versus the Zacks Consensus Estimate of a $0.29 loss, and revenue of $1.16 million missed the consensus estimate by 14.15%.
Why it matters
The estimate revisions trend ahead of the release was unfavorable, translating into a Zacks Rank #5 (Strong Sell), and the shares are expected to underperform the market in the near future. The company has not beaten consensus revenue estimates over the last four quarters.
Market: -0.6% today ($172.92), +25.9% YTD, 0.8x vol — as of 00:45 UTC